Neuberger Berman Group
IPSC icon

Neuberger Berman Group’s Century Therapeutics IPSC Stock Holding History

Neuberger Berman Group’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,056
Closed -$66.6K – 1875
2023
Q4 		$66.6K Buy
+20,056
New +$36.5K ﹤0.01% 1821

Other funds holding IPSC

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Neuberger Berman Group's IPSC Position: Q1 2024 in Review

Neuberger Berman Group sold out of Century Therapeutics (IPSC) in Q1 2024, closing a stake of 20,056 shares — an estimated $66.6K sold.

Neuberger Berman Group first reported a position in IPSC in Q4 2023 and held it in 1 quarter. The position peaked at $66.6K in Q4 2023. 67 funds tracked by Wall St. Rank hold IPSC as of Q1 2024.

  • Neuberger Berman Group reported no remaining Century Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Neuberger Berman Group sold 20,056 Century Therapeutics shares in Q1 2024, an estimated $66.6K.
  • Neuberger Berman Group first reported a position in Century Therapeutics in Q4 2023 and held it in 1 quarter.
  • Neuberger Berman Group's Century Therapeutics position peaked at $66.6K in Q4 2023.
  • 67 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2024.

Based on Neuberger Berman Group's 13F filing for Q1 2024, filed 13 May 2024.